With the development of Artificial Intelligence and its widespread use, the pharma industry is at a crossroads where it will have to decide how it will conduct research-innovation-development in this sector of activity, if AI is to take over an important part of pharmaceutical R and D or if AI will only assist specialist staff in certain segments of drug and vaccine innovation for future diseases.
